You are here>>Home
 
 

Shenogen is a new drug discovery and development venture focused on the discovery and development of small molecule and biologic drugs targeted at the novel Estrogen Receptor (ER) variant we have recently discovered and characterized.
Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.  By leveraging our unique combination of expertise on traditional Chinese herbal formulations with long history of human usage and our proprietary receptor-based bioassays, we have screened and identified a number of naturally derived bioactive chemical compounds specifically targeting the novel ER receptor. Based on the chemical structures of these lead compounds, we are developing a pipeline of drug candidates targeting estrogen-related disease indications.&......

 
 
  • Genetic Cause of Most Common Form of Breast Cancer Identified

  • Shenogen Pharm's Scientific Advisor V. Craig Jordan Elceted to National Academy of Science

  • Shenogen Wins "Most Promising Company" Award at ChinaBio
  • New Universal Breast Cancer Marker Predicts Recurrence And Clinical Outcome

  • China Biotech in Review: Company Profiles and Drug Advancement
  •    
    Copyright ® 2007-2008, Shenogen Pharma Group ¤¤ Privacy Statement ¤ JingICP Code : 08001919 ¤ Technical Support:JiaHeng Era